Ardelyx, Inc PT receives Investment Bank Analyst Rating Update
As we head into the new week, keep an eye on these stocks that Wall Street analysts upgraded or initiated positively last week, all first covered on InvestingPro+. 1. Advanced...
Insider and hedge fund activity can serve as useful bellwethers for investors. Here are some of the biggest such moves from the past week, as first reported on InvestingPro+. Hedge...
The market expects Ardelyx (NASDAQ:ARDX) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2020. This...
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) amended its collaboration agreement with UK-based pharma giant AstraZeneca (NYSE:AZN) related to development and commercialization...
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
|Average||5.183 (+191.36% Upside)|
|No. of Analysts||6|